Loading…
← CockpitCompetitor Analysis › AVR Anteris Technologies Global Corp.Open in the cockpit ↗

Anteris Technologies Global Corp.AVRCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties
Momentum laggard 11
Mkt cap
$508M
US dollars, full cap
Free float
83%
of shares outstanding
$/day
$8.45M
20-day average traded
P/B
2.24×
price to book
ROE
-93.8%
delivered
Implied ROE
30.2%
what the price asks
Next earnings
119 days
17 Mar 2027
Close · USD$5.21
1D-2.1%
1W-16.0%
1M-17.2%
3M-43.7%
6M-39.6%
YTD+4.4%
1Y+45.9%
ATR %7.6%
Beta1.51
52w lowhigh52.9% off high

What Anteris Technologies Global does

Employees: 174

Anteris Technologies Global at a glance

Size Anteris Technologies Global (AVR) is a United States Health Care company (Medical Specialties) with a market value of $508M, the 2661st largest of 3,085 United States companies the cockpit tracks. Shares closed at $5.21 on 18 Nov 2026.

Performance Over six months the shares fell 39.6%, against -16.1% for the median peer and -2.2% for the United States market (cap-weighted) — 4th lowest of 21 in its peer set.

Growth Revenue grew 9.0% over the last twelve months (peer median +6.3%); the operating margin is -4,880.4% (peer median 3.5%).

Valuation It trades at 2.24× book value against a peer median of 1.57× (6th most expensive of 20).

Price implies The share price implies a return on equity of about 30.2%; Anteris Technologies Global delivers -93.8%, so the price asks more than the business earns today.

Short interest Short interest is 9.3% of the free float (30 Oct 2026).

Next results Next results expected around 17 Mar 2027 (exchange calendar; dates can move).

Relative performance

608010012021 May 202621 Aug 202618 Nov 2026Peer median 85AVR 58
Six months, rebased to 100: Anteris Technologies Global against the median of its 20 peers (local-currency closes).

Anteris Technologies Global financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$2.33M$1.91M$2.70M$2.73M$3.20M
Revenue growth—-29%-1%-15%—
Gross profit-$49,000-$317,000-$241,000-$280,923-$475,694
EBITDA-$112M-$92.2M-$76.9M-$46.2M-$32.0M
Net income-$108M-$94.1M-$76.3M-$46.0M-$30.6M
Free cash flow-$93.5M-$79.8M-$63.5M-$37.0M-$31.0M
Capital expenditure$2.62M$1.95M$2.28M$2.39M$1.67M
Total debt$16.1M$2.28M$1.40M$1.69M$952,787

Quarterly statements and history in the cockpit →

Anteris Technologies Global competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%6880757979300639688298688580NNNN300439MEDX603520RCELMYGNZJYL002932CEVI605369ANGO603309AVR6-month return →1-month return →
Up and to the right = strong over both horizons. Anteris Technologies Global is the large dot.

Fundamentals: return on equity against price-to-book

-100%-50%0%20×40×6880757979300639688298688580NNNN300439603520MYGNZJYL301033300246CEVIANGOAVRReturn on equity →Price / book →
A bank or insurer earning more on its equity usually trades at a higher multiple of book; points far above the trend are priced for more. Anteris Technologies Global is the large dot.

Capital: ROE delivered against the ROE the price implies

-100%-50%0%-100%-50%0%6880757979300639688298688580MYGN300246ANGOAVRROE delivered →ROE the price implies →
Above the diagonal = the price asks for a higher return on equity than the business earns today. Anteris Technologies Global is the large dot.

Anteris Technologies Global competitors and peer comparison

How Anteris Technologies Global compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Anteris Technologies Global against its 20 peers (data as of 18 Nov 2026)
MeasureAVRPeer medianRank in peer set
1-month return-17.2%-3.8%2nd lowest of 21
6-month return-39.6%-16.1%4th lowest of 21
Return on equity-93.8%1.8%lowest of 20
Price / book2.24×1.57×6th most expensive of 20
ROE the price implies30.2%11.8%2nd most demanding of 20
ROE delivered-93.8%1.8%lowest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthROEPrice / bookImplied ROEDelivered ROE
Anteris Technologies Global AVRUnited States$508M-40%+9%-94%2.24×30.2%-93.8%
Assure Tech (Hangzhou) 688075.SSChina$508M-27%-9%0%0.67×6.4%-0.5%
Shofu 7979.TJapan$510M+32%+9%13%1.57×7.6%12.9%
Guangdong Hybribio Biotech 300639.SZChina$511M-18%-7%2%0.85×5.0%1.8%
Zhejiang Orient Gene Biotech 688298.SSChina$500M-27%+18%-11%0.56×5.3%-10.9%
Nanjing Vishee Medical Technology 688580.SSChina$499M-43%+7%9%1.94×21.7%9.5%
Anbio Biotechnology NNNNUnited States$518M-89%+10%27%4.46×79.1%n/a
MedicalSystem Biotechnology 300439.SZChina$518M-9%+14%3%1.14×7.9%3.4%
medmix MEDX.SWSwitzerland$494M+11%-7%0%0.97×6.4%0.0%
Zhejiang Starry Pharmaceutical 603520.SSChina$491M-44%+9%1%1.33×11.8%1.1%
AVITA Medical RCELUnited States$529M+290%+17%n/an/an/an/a
Myriad Genetics MYGNUnited States$530M+45%-3%-40%1.97×23.1%-40.2%
Jin Medical International ZJYLUnited States$532M+47%-14%4%0.87×17.8%4.0%
Wuhan Easy Diagnosis Biomedicine 002932.SZChina$485M-14%-9%-1%0.55×3.1%-1.2%
Hangzhou Alltest Biotech 688606.SSChina$484M-20%0%3%0.82×5.4%3.0%
Medprin Regenerative Medical Technologies 301033.SZChina$482M-14%+23%16%3.71×18.3%15.8%
Guangdong Biolight Meditech 300246.SZChina$478M-35%+7%-10%2.91×18.4%-10.2%
CellaVision CEVI.STSweden$477M+64%+2%15%5.20×21.5%15.5%
Zhejiang Gongdong Medical Technology 605369.SSChina$542M-21%+6%4%2.07×18.2%4.1%
AngioDynamics ANGOUnited States$476M-4%+8%-19%2.93×13.4%-19.2%
WELL LEAD MEDICAL 603309.SSChina$473M-22%+1%2%1.73×9.3%1.8%

Questions

Which companies are Anteris Technologies Global's closest peers?
The cockpit's peer set: Assure Tech (Hangzhou) (688075.SS), Shofu (7979.T), Guangdong Hybribio Biotech (300639.SZ), Zhejiang Orient Gene Biotech (688298.SS), Nanjing Vishee Medical Technology (688580.SS), Anbio Biotechnology (NNNN), MedicalSystem Biotechnology (300439.SZ), medmix (MEDX.SW).
Is Anteris Technologies Global expensive compared with its peers?
On price / book it trades at 2.24× against a peer median of 1.57×, 6th most expensive of 20 in its peer set. The share price implies a return on equity of about 30.2%; Anteris Technologies Global delivers -93.8%, so the price asks more than the business earns today.
How has Anteris Technologies Global stock performed?
Over six months to 18 Nov 2026 the shares returned -39.6% against -16.1% for the median peer; over one year +45.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.